Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial

Randomized Controlled Trial

Rezvan Salehidoost et al. Sci Rep. 2022.

Abstract

To evaluate the effect of magnesium supplementation on insulin resistance and cardiovascular markers in people with prediabetes. A 12 week double-blind placebo-controlled randomized clinical trial was conducted at Isfahan Endocrine and Metabolism Research Center, Iran, on people with prediabetes (n = 86) to compare the effects of magnesium oxide 250 mg/day versus a placebo on anthropometric indices, blood pressure, fasting glucose, insulin, HOMA-IR index, C-reactive protein, uric acid and lipid profile. Both groups had similar distributions of anthropometric and biochemical variables at baseline. Those who received magnesium supplementation had significantly higher levels of HDL-cholesterol compared to the placebo group at the end of the study (49.7 ± 10.9 vs 43.6 ± 7.2 mg/dL, P = 0.003). The mean changes of HOMA-IR index, total cholesterol, LDL-cholesterol, triglyceride, uric acid and C-reactive protein levels as well as anthropometric indices and blood pressure in supplemented and placebo groups did not differ significantly. Magnesium supplementation increased HDL-cholesterol levels in people with prediabetes. However, other cardiometabolic markers were not improved by magnesium supplementation at the above dosage and duration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1

Flow diagram of participants.

References

1. Eckel RH, et al. Obesity and type 2 diabetes: What can be unified and what needs to be individualized? Diabetes Care. 2011;34:1424–1430. doi: 10.2337/dc11-0447. - DOI - PMC - PubMed
1. Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care. 2014;37:2668–2676. doi: 10.2337/dc14-0817. - DOI - PMC - PubMed
1. American Diabetes Association Professional Practice Committee 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45:S144–S174. doi: 10.2337/dc22-S010. - DOI - PubMed
1. American Diabetes Association Professional Practice Committee 11. Chronic kidney disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45:S175–S184. doi: 10.2337/dc22-S011. - DOI - PubMed
1. American Diabetes Association Professional Practice Committee 12. Retinopathy, neuropathy, and foot care: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45:S185–S194. doi: 10.2337/dc22-S012. - DOI - PubMed

Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial - PubMed (original) (raw)